HighTower Advisors’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
Other funds holding FATE
HighTower Advisors's FATE Position: Q3 2026 in Review
HighTower Advisors reduced its Fate Therapeutics (FATE) stake by 4.3% in Q3 2026, selling an estimated $3.76K and leaving 32,000 shares worth $75.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3712.
HighTower Advisors first reported a position in FATE in Q1 2021 and has held it in 23 quarters since. The position peaked at $1.19M in Q2 2021. 105 funds tracked by Wall St. Rank hold FATE as of Q3 2026.
- HighTower Advisors held 32,000 shares of Fate Therapeutics worth $75.8K as of Q3 2026.
- HighTower Advisors sold 1,454 Fate Therapeutics shares in Q3 2026, an estimated $3.76K.
- Fate Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3712 holding.
- HighTower Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 23 quarters since.
- HighTower Advisors's Fate Therapeutics position peaked at $1.19M in Q2 2021.
- 105 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.